How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients

Coyle, Conor, Watson, Lily, Whately-Smith, Caroline, Brooke, Mel, Kiltz, Uta, Lubrano, Ennio, Queiro, Ruben, Trigos, David, Brandt-Juergens, Jan, Choy, Ernest ORCID: https://orcid.org/0000-0003-4459-8609, D'Angelo, Salvatore, Delle Sedie, Andrea, Dernis, Emmanuelle, Wirth, Théo, Guis, Sandrine, Helliwell, Philip, Ho, Pauline, Hueber, Axel, Joven, Beatriz, Koehm, Michaela, Morales, Carlos Montilla, Packham, Jon, Pinto Tasende, Jose Antonio, Ramírez, Julio, Ruyssen-Witrand, Adeline, Scrivo, Rossana, Twigg, Sarah, Welcker, Martin, Soubrier, Martin, Gossec, Laure and Coates, Laura C. 2024. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology 10.1093/rheumatology/kead679

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Objectives The AsseSSing Impact in pSoriatic Treatment (ASSIST) study investigated prescribing in routine PsA care and whether the patient-reported outcome—PsA Impact of Disease questionnaire (PsAID-12)—impacted treatment. This study also assessed a range of patient and clinician factors and their relationship to PsAID-12 scoring and treatment modification. Methods Patients with PsA were selected across the UK and Europe between July 2021 and March 2022. Patients completed the PsAID questionnaire and the results were shared with their physician. Patient characteristics, disease activity, current treatment methods, treatment strategies, medication changes and patient satisfaction scores were recorded. Results A total of 503 patients were recruited. Some 36.2% had changes made to treatment, and 88.8% of these had treatment escalation. Overall, the mean PsAID-12 score was higher for patients with treatment escalation; increase in PSAID-12 score is associated with increased odds of treatment escalation (odds ratio 1.58; P < 0.0001). However, most clinicians reported that PsAID-12 did not impact their decision to escalate treatment, instead supporting treatment reduction decisions. Physician’s assessment of disease activity had the most statistically significant effect on likelihood of treatment escalation (odds ratio 2.68, per 1-point score increase). Escalation was more likely in patients not treated with biologic therapies. Additional factors associated with treatment escalation included: patient characteristics, physician characteristics, disease activity and disease impact. Conclusion This study highlights multiple factors impacting treatment decision-making for individuals with PsA. PsAID-12 scoring correlates with multiple measures of disease severity and odds of treatment escalation. However, most clinicians reported that the PsAID-12 did not influence treatment escalation decisions. Psoriatic Arthritis Impact of Disease (PsAID) scoring could be used to increase confidence in treatment de-escalation.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Medicine
Publisher:	Oxford University Press
ISSN:	1462-0324
Date of First Compliant Deposit:	2 February 2024
Date of Acceptance:	23 November 2023
Last Modified:	06 Feb 2024 13:00
URI:	https://orca.cardiff.ac.uk/id/eprint/166117

Actions (repository staff only)

Edit Item